- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Immunome Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.04. | Immunome files to sell 2.18M common shares for holders | 3 | Seeking Alpha | ||
| 28.03. | Immunome Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 28.03. | Immunome GAAP EPS of -$5.38 | 1 | Seeking Alpha | ||
| 26.03. | Immunome Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.03. | Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome | 97 | GlobeNewswire (Europe) | MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced... ► Artikel lesen | |
| 18.03. | Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies | 325 | Business Wire | Arrayjet's patented spot-on-spot microarray screening technology is available for customers to adopt in-house and via Arrayjet's CRO/CMO services Immunome signs deal to use Arrayjet platform... ► Artikel lesen | |
| 20.02. | Immunome completes enrollment for AL102 Phase 3 study | 3 | Investing.com | ||
| 16.02. | Immunome completes $230 million stock offering | 4 | Investing.com | ||
| 14.02. | Immunome slides on $200 million equity offering | 1 | Reuters | ||
| 14.02. | Immunome edges up after $200 million equity offering | 2 | Reuters | ||
| 14.02. | Immunome down 1%, prices $200M equity | 2 | Seeking Alpha | ||
| 14.02. | Immunome Prices Public Offering Of 10 Mln Shares At $20/Shr | - | RTTNews | ||
| 13.02. | Immunome announces $200 million stock offering | 1 | Investing.com | ||
| 13.02. | Immunome files for automatic mixed securities shelf | 2 | Seeking Alpha | ||
| 07.02. | Immunome wins Ayala's Phase III desmoid tumour candidate for $50m | 4 | Pharmaceutical Technology | ||
| 07.02. | Immunome To Buy AL102 From Ayala Pharmaceuticals, A Phase 3 Asset For Treating Desmoid Tumors | 3 | pulse2.com | ||
| 07.02. | Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up | 1 | Zacks | ||
| 06.02. | Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks | 6 | FierceBiotech | ||
| 06.02. | Immunome To Acquire AL102, AL101 Drug Candidates From Ayala Pharma | 3 | RTTNews |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 104,10 | +3,19 % | MODERNA: Bereit fürs Comeback? | Im August 2021 hatte die MODERNA-Aktie ihr Allzeithoch bei 497 $ erreicht. Seit 2023 sind nach Ende des Corona-Impfstoffbooms wieder rote Zahlen angesagt. Das Ergebnis je Aktie (Eps) lag für 2023 bei... ► Artikel lesen | |
| EPIGENOMICS | 1,545 | -5,21 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 51,50 | +1,88 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting | ||
| DEFENCE THERAPEUTICS | 0,832 | -2,12 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 1,000 | +16,25 % | Ginkgo Bioworks surges as much as 31%, though pares gains | ||
| OCULAR THERAPEUTIX | 4,686 | +5,66 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy | 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,225 | +4,05 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,030 | +1,98 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,470 | +4,31 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| MACROGENICS | 13,650 | +0,52 % | MacroGenics, Inc.: MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures | Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,880 | +1,24 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,842 | +7,18 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| CORCEPT THERAPEUTICS | 21,160 | -0,75 % | Corcept Therapeutics Incorporated: Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call | ||
| SIGA TECHNOLOGIES | 9,020 | +2,62 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| ULTRAGENYX | 42,200 | +1,93 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update |
IMMUNOME INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,68 % bei einem Aktienkurs von 13,960 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
